Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
The University of Texas MD Anderson Cancer Center · Duke Medical Center · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
562
total citations
- FWCI
- 28.17
- Percentile
- 100%
- References
- 33
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Pertuzumab
- Medicine
- Trastuzumab
- Internal medicine
- Colorectal cancer
- Metastatic breast cancer
- Oncology
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- CPCancer Prevention and Research Institute of TexasAward: RP1100584
- UOUniversity of Texas MD Anderson Cancer CenterAward: P30 CA016672
- CFCenter for Clinical and Translational Sciences, University of Texas Health Science Center at HoustonAward: P30 CA016672
- NCNational Center for Advancing Translational SciencesAward: UL1 TR000371
- SKSheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy